Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

Francesco Orio, Stefano Palomba, Teresa Cascella, Libuse Tauchmanovà, Luciano G. Nardo, Sebastiano Di Biase, Donato Labella, Tiziana Russo, Silvia Savastano, Achille Tolino, Fulvio Zullo, Annamaria Colao, Gaetano Lombardi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml ± SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalReproductive BioMedicine Online
Volume9
Issue number5
Publication statusPublished - Nov 2004

Fingerprint

Polycystic Ovary Syndrome
Plasminogen Activator Inhibitor 1
Body Mass Index
Homeostasis
Serum
Weights and Measures
Control Groups
Age Groups
Obesity
Morbidity

Keywords

  • Cardiovascular risk
  • Insulin resistance
  • PAI-1 activity
  • Polycystic ovary syndrome (PCOS)

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Orio, F., Palomba, S., Cascella, T., Tauchmanovà, L., Nardo, L. G., Di Biase, S., ... Lombardi, G. (2004). Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive BioMedicine Online, 9(5), 505-510.

Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? / Orio, Francesco; Palomba, Stefano; Cascella, Teresa; Tauchmanovà, Libuse; Nardo, Luciano G.; Di Biase, Sebastiano; Labella, Donato; Russo, Tiziana; Savastano, Silvia; Tolino, Achille; Zullo, Fulvio; Colao, Annamaria; Lombardi, Gaetano.

In: Reproductive BioMedicine Online, Vol. 9, No. 5, 11.2004, p. 505-510.

Research output: Contribution to journalArticle

Orio, F, Palomba, S, Cascella, T, Tauchmanovà, L, Nardo, LG, Di Biase, S, Labella, D, Russo, T, Savastano, S, Tolino, A, Zullo, F, Colao, A & Lombardi, G 2004, 'Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?', Reproductive BioMedicine Online, vol. 9, no. 5, pp. 505-510.
Orio F, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive BioMedicine Online. 2004 Nov;9(5):505-510.
Orio, Francesco ; Palomba, Stefano ; Cascella, Teresa ; Tauchmanovà, Libuse ; Nardo, Luciano G. ; Di Biase, Sebastiano ; Labella, Donato ; Russo, Tiziana ; Savastano, Silvia ; Tolino, Achille ; Zullo, Fulvio ; Colao, Annamaria ; Lombardi, Gaetano. / Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. In: Reproductive BioMedicine Online. 2004 ; Vol. 9, No. 5. pp. 505-510.
@article{687dc89c0fe9479dad673f0c97a1b4b6,
title = "Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?",
abstract = "This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml ± SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.",
keywords = "Cardiovascular risk, Insulin resistance, PAI-1 activity, Polycystic ovary syndrome (PCOS)",
author = "Francesco Orio and Stefano Palomba and Teresa Cascella and Libuse Tauchmanov{\`a} and Nardo, {Luciano G.} and {Di Biase}, Sebastiano and Donato Labella and Tiziana Russo and Silvia Savastano and Achille Tolino and Fulvio Zullo and Annamaria Colao and Gaetano Lombardi",
year = "2004",
month = "11",
language = "English",
volume = "9",
pages = "505--510",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

AU - Orio, Francesco

AU - Palomba, Stefano

AU - Cascella, Teresa

AU - Tauchmanovà, Libuse

AU - Nardo, Luciano G.

AU - Di Biase, Sebastiano

AU - Labella, Donato

AU - Russo, Tiziana

AU - Savastano, Silvia

AU - Tolino, Achille

AU - Zullo, Fulvio

AU - Colao, Annamaria

AU - Lombardi, Gaetano

PY - 2004/11

Y1 - 2004/11

N2 - This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml ± SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.

AB - This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml ± SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.

KW - Cardiovascular risk

KW - Insulin resistance

KW - PAI-1 activity

KW - Polycystic ovary syndrome (PCOS)

UR - http://www.scopus.com/inward/record.url?scp=8744223271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744223271&partnerID=8YFLogxK

M3 - Article

C2 - 15588467

AN - SCOPUS:8744223271

VL - 9

SP - 505

EP - 510

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 5

ER -